Fig. 2From: Would treatment decisions about secondary prevention of CVD based on estimated lifetime benefit rather than 10-year risk reduction be cost-effective?Diagrammatic representation of the micro-simulation model with health states (boxes) and possible transitions (arrows)Back to article page